#United States #oncology #AbbVie #North Chicago #ASCO 2026

AbbVie Showcases Promising Oncology Developments at ASCO 2026

On May 21, 2026, AbbVie (NYSE: ABBV) presented remarkable new data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago. This data highlights ongoing advancements in AbbVie's oncology pipeline, which targets both solid and hematologic cancers. Key presentations included updates on prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer, and multiple myeloma, showcasing promising results from innovative therapies.

Encompassing a variety of methodologies, AbbVie’s oncology pipeline is designed to address the complex and heterogeneous nature of cancer biology. The presentation featured information on Topoisomerase I (Top1i) inhibitor-based antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), underscoring the company's continued investment in expanding these platforms.

Dr. Daejin Abidoye, Vice President and Therapeutic Area Head of Oncology, Solid Tumor and Hematology at AbbVie, commented on the pipeline’s design: “Our oncology pipeline is intentionally created to respond to the biological complexities and variabilities of cancers through a diverse portfolio of differentiated therapies. The data we present at ASCO demonstrates the robustness of this strategy, particularly in the ADC program targeting solid tumors and in the efficacy of our next-generation TCE, etentamig, currently under development for multiple myeloma. These results exemplify our commitment to advancing unique scientific approaches that meet significant unmet patient needs.”

The highlighted results from the ASCO presentations included:

• - Data from AbbVie’s Top1i ADC for Solid Tumors: In a Phase 1 trial (NCT06318273) evaluating the promising first-in-class bispecific ADC candidate ABBV-969A in metastatic castration-resistant prostate cancer (mCRPC) patients with multiple prior therapies, an objective response rate (ORR) of 45% was observed among 29 patients with lesions measurable by RECIST criteria. Furthermore, 67% of those achieved a reduction of more than 50% in prostate-specific antigen (PSA) levels (PSA50), and 28% reached PSA90. The safety profile for heavily pretreated mCRPC patients was manageable, with additional results expected to be detailed at the annual meeting.

• - Small Cell Lung Cancer (SCLC) Findings: The data from the Phase 1 trial of ABBV-706 (NCT05599984), targeting SEZ6, indicated an ORR of 82% among SCLC patients receiving single-agent treatment post-second-line therapy at a recommended phase 3 dose of 1.8 mg/kg. This is notably positive given the poor prognosis typically associated with SCLC. The safety profile maintained consistency with previously reported data, with further results to be shared at the annual meeting to support continued evaluation of ABBV-706.

• - Platinum-Resistant Ovarian Cancer (PROC) and Head and Neck Squamous Cell Carcinoma (HNSCC): The Phase 1 basket trial data for the next-generation ADC telisotuzumab adizutecan (Temab-A) indicated promising anti-tumor activity in PROC (NCT06084481) and HNSCC patients without biomarker selection. Results for patients with c-Met selection are also anticipated, further supporting Temab-A's potential among expanding solid tumors.

• - Relapsed/Refractory Multiple Myeloma: In the Phase 1b trial (NCT05650632), the next-generation B-cell maturation antigen (BCMA) x CD3 T-cell engager etentamig was evaluated in R/R MM patients previously treated with BCMA-targeting therapies. Among the 11 patients transitioning to etentamig, an ORR of 64% was noted, with 67% achieving minimal residual disease negativity. The median duration of response was reported as 13 months. Importantly, no new safety signals were identified, with a manageable cytokine release syndrome reported.

For ongoing updates on AbbVie’s clinical trials and further information, visit ClinicalTrials.gov. The complete archives for the 2026 ASCO annual meeting can be accessed for all highlighted abstracts.

About AbbVie

AbbVie's mission is to provide innovative medications and solutions to address serious health challenges, tackling difficult medical issues of the future. The company focuses on enhancing the lives of patients in areas such as immunology, neuroscience, oncology, and aesthetic medicine, utilizing diverse modalities and biological approaches for developing targeted therapies. To learn more about AbbVie, visit www.abbvie.com or follow them on social media platforms.